β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia
about
Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial.Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases.Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia.Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.Novel prognostic scoring system for diffuse large B-cell lymphoma.
P2860
β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
β2 -microglobulin normalizatio ...... h chronic lymphocytic leukemia
@ast
β2 -microglobulin normalizatio ...... h chronic lymphocytic leukemia
@en
type
label
β2 -microglobulin normalizatio ...... h chronic lymphocytic leukemia
@ast
β2 -microglobulin normalizatio ...... h chronic lymphocytic leukemia
@en
prefLabel
β2 -microglobulin normalizatio ...... h chronic lymphocytic leukemia
@ast
β2 -microglobulin normalizatio ...... h chronic lymphocytic leukemia
@en
P2093
P2860
P50
P356
P1433
P1476
β2 -microglobulin normalizatio ...... h chronic lymphocytic leukemia
@en
P2093
Jan A Burger
Lianchun Xiao
Nitin Jain
Philip A Thompson
Susan M O'Brien
Xuemei Wang
P2860
P304
P356
10.1002/CNCR.29794
P407
P577
2015-11-20T00:00:00Z